Saturday, March 31, 2012

Thursday, March 29, 2012

In the News: Telomeres and HIVAN

Why is HIVAN or idiopathic collapsing glomerular disease different than standard FSGS? It is more proliferative compared to a podocytopenia seen in other forms of FSGS.  The questions have been thrown out there multiple times.  Studies in past have shown that the podocytes in the collapsing variant are premature form and then proliferate.  Telomerase protein is responsible for aging.  Two components called TERT and TERC are important.  A study showed that transgenic TERT expression in mice induced up regulation of Wnt signaling and leading to disruption of glomerular structure and resulting in collapsing glomerulopathy.  Then they showed that the humans and mice had increased expression of the TERT and activation of Wnt signaling in HIVAN models.   This was inhibited by a Dkk1( inhibitor of the Wnt expression).  The pathology changes were reversible.  Interesting, as this suggests that the process might be reversible.  Perhaps medications that use a Dkk1 might help? This adds to a novel understanding of collapsing GN that was not known before.

Take a look at this paper from Stanford and Columbia group
http://www.ncbi.nlm.nih.gov/pubmed/22138751

Wednesday, March 28, 2012

History of Erythropoietin development

1878: Bert and Jourdanet described symptoms of anemia and mountain sickness from hypoxia
1906: Carnot and Deflandre observed that serum from an anemic donor rabbit injected in normal rabbits resulted in increased erythropoiesis.  It was initially called hematopoietin: potential circulating factor
1953: Erslev demonstrated that plasma from anemic rabbits contained a factor capable of stimulating erythropoiesis and predicted its potential as a treatment modality. Did a quantitative infusion study regarding this notion as well.
1957: Jacobson and other such as Goldwasser found that the kidney was the source of this hormone that controlled the production via experiments with each organ being removed in animals.
1985: Few milligrams of erythropoietin from over 2.5L of urine of patients with aplastic anemia was collected and purified by Miyake et al
1985: The human erythropoietin gene was cloned
1985: Eshbach et al had the the first treatment of someone with initially just 2.5 units/kg on dialysis followed by no response and then increased dose of 15 units/kg with good response leading to potential treatment success.
1985: Mass effort to large scale production
1989: FDA approves recombinant EPO for use in chronic renal failure patients on dialysis
1990: FDA approves recombinant EPO for use in chronic renal failure without dialysis and other non renal causes.

A good references that summarize as above is
http://www.nephrologyrounds.org/crus/nephUS_0304.pdf

Monday, March 26, 2012

Bundling and the DOPPS data

Currently as we bundle along the dialysis treatment and anemia treatment along with IV medications and antibiotics needed for dialysis access care, future is looking at 2014 to possibly include sensipar.  It also appears that there might be a switch to giving more PO vitamin D rather than IV Vitamin D during dialysis as well.
How is this going to affect the patients? Most of our dialysis patients take many medications already.  Asking them to take more PO medications will be a concern.  Lot of these questions will arise. Lot of these questions arose when bundling was first proposed.  Did the renal community do ok with the bundling. Recently at a local NKF meet, Dr. Jay Wish presented the DOPPS data that is freely available on their website at http://www.dopps.org/annualreport/index.htm on different parameters.

Some interesting findings in Anemia and bone disease and hospitalization:
1. Average Hgb has decreased in USA after the June 2011 ESA labeling from 11.4 to mean of 11.2.  IN general, the range is narrowing and very few percentages are >12 and <10.  
2. Sharpest decline was in the patients with Hgb greater than 12g/dl
3. Mean epo dose decreased by 15% from 2010 to 2011 August, greatest happening after June 2011.
4. IV Iron use has risen
5. Serum ferritin levels are rising in some cases, >1200 ng/ml in 11%

Pth/Bone disease
1. No major changes in pth levels, continue to increase ( as bar was raised to 600 from 300)
2. No change in use of sensipar
3. Small units using more PO vitamin D rather then IV vitamin D

Hospitalization rates have increased in last one year( cause unknown)

take a complete look at the PDF on their website.

Saturday, March 24, 2012

IN THE NEWS: Stem cells and transplantation

Stem cell transplantation and Kidney transplantation has been tried at few centers now as a form to minimize immunosuppression. But inducting with autologous mesenchymal stem cells is a novel thought. A randomized controlled trial just published in JAMA from China and Miami, Florida.  A single center, prospective, open label, randomized study was done from 2008-2009.  The intervention arm had patients inoculated with marrow derived autologous mesenchymal stem cells at the time of kidney repercussion and then 2 weeks later.  They then received either low dose calcinuerin inhibitors or regular dose.  The control group got anti IL-2 induction and standard dose calcineurins inhibitors.
Acute rejection at one year was the major outcome they measured.  At 30 months,the patient and graft survival was same in both groups. Overall, there was less rejection, less infections and better renal function at one year in the stem cell arm compared to standard arm.  Initial recovery of renal function after surgery was also faster in stem cell arm.

This study is a first of its kind and will spark some major centers in US to hopefully consider this modality  to be tested again. Before we move to this as a true replacement for induction treatment, this needs to be reproduced at other centers.

Take a look. Hoping one of the renal journals might have a commentary on this soon
http://jama.ama-assn.org/content/307/11/1169.short


Friday, March 23, 2012

MPGN revisited

This week in the March 2012 issue of NEJM, Sethi and Fervenza discuss a must read article on MPGN. All the recent advances in MPGN and so called C3 glomerulopathy have been reviewed in this article.

Key points
1. EM based approach should be abandoned.  IF based approach seems more logical.
2. Immune complex mediated vs complement mediated MPGN and then looking for secondary causes.
3. Immune complex mediated usually has circulating Immunoglobulin and immune complexes and the big 3 categories are infections, autoimmune disease and MGUS. IF will show C3 and some immunoglobulin.
4. The complement based MPGN usually have capillary wall staining for C3 deposits, then  look at the EM --> if sausage shaped deposits think dense deposit disease and if not then C3 glomerular disease. Both of these are a result of dysregulation of the alternative pathway of complement.
5. Recurrence after transplantation is fair amount, The highest being if this MPGN was associated with MGUS.

Take a look at this nice summary on MPGN
Ref:
http://www.ncbi.nlm.nih.gov/pubmed/22435371

All Posts

Search This Blog